Form F-1 - Registration statement for certain foreign private issuers:
SEC Accession No. 0001193125-25-224077
Filing Date
2025-09-30
Accepted
2025-09-30 08:00:49
Documents
18

Document Format Files

Seq Description Document Type Size
1 F-1 d911523df1.htm F-1 505053
2 EX-5.1 d911523dex51.htm EX-5.1 69314
3 EX-23.1 d911523dex231.htm EX-23.1 1735
4 EX-23.2 d911523dex232.htm EX-23.2 1729
5 EX-FILING FEES d911523dexfilingfees.htm   iXBRL EX-FILING FEES 18615
6 GRAPHIC g911523dsp1.jpg GRAPHIC 15324
7 GRAPHIC g911523dsp2.jpg GRAPHIC 6781
8 GRAPHIC g911523g70e73.jpg GRAPHIC 31973
  Complete submission text file 0001193125-25-224077.txt   795291

Data Files

Seq Description Document Type Size
20 EXTRACTED XBRL INSTANCE DOCUMENT d911523dexfilingfees_htm.xml XML 5273
Mailing Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW Australia 2000
Business Address THREE INTERNATIONAL TOWERS LEVEL 24, 300 BARANGAROO AVENUE SYDNEY NSW Australia 2000 01161298780088
KAZIA THERAPEUTICS LTD (Filer) CIK: 0001075880 (see all company filings)

EIN.: 000000000 | State of Incorp.: C3 | Fiscal Year End: 0630
Type: F-1 | Act: 33 | File No.: 333-290598 | Film No.: 251358192
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)